HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

MIB-1 and DNA topoisomerase II alpha could be helpful for predicting long-term survival of patients with glioblastoma.

Abstract
Approximately 10% of patients with glioblastoma survive more than 2 years after diagnosis. Distinguishing these patients from those who died within 2 years of diagnosis is clinically significant. We studied the MIB-1 labeling index (LI) and DNA topoisomerase II alpha LI of glioblastomas from 34 patients who lived for more than 2 years after diagnosis and of glioblastomas from 34 age- and sex-matched control patients who died within 2 years of diagnosis. The means of MIB-1 and topoisomerase II alpha LIs of the group with a better outcome were lower. With 35 as the cutoff point for the MIB-1 LI and 26 as the cutoff point for the topoisomerase II alpha LI, both MIB-1 and topoisomerase II alpha LIs were related significantly to survival. Our study showed that both MIB-1 and topoisomerase II alpha could help predict long-term survival of patients with glioblastomas. Multivariate analyses revealed that MIB-1 was a better prognostic marker than topoisomerase II alpha.
AuthorsDonald Ming-Tak Ho, Chih-Yi Hsu, Ling-Tan Ting, Hung Chiang
JournalAmerican journal of clinical pathology (Am J Clin Pathol) Vol. 119 Issue 5 Pg. 715-22 (May 2003) ISSN: 0002-9173 [Print] England
PMID12760291 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, Neoplasm
  • DNA-Binding Proteins
  • Ki-67 Antigen
  • DNA Topoisomerases, Type II
Topics
  • Adolescent
  • Adult
  • Antigens, Neoplasm
  • Brain Neoplasms (diagnosis, metabolism)
  • Child
  • Child, Preschool
  • DNA Topoisomerases, Type II (analysis)
  • DNA-Binding Proteins
  • Female
  • Glioblastoma (diagnosis, metabolism)
  • Humans
  • Immunohistochemistry
  • Ki-67 Antigen (analysis)
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Prognosis
  • Survivors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: